Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Overview of preclinical and phase II clinical studies on Pegmolesatide’s long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction

Fig. 1

Unique EPOR binding properties of Pegmolesatide. A The sequence and structure of Pegmolesatide. B The EPOR (EC domain, Ig Fc fusion) was immobilized on Biacore chips at 900 RU density. Ligands were then introduced and for the time courses shown, binding was assayed. The peptide dimer refers to the non-PEGylated Pegmolesatide. C Competitive displacement IC50 of Pegmolesatide and ESPO 3000 by EPO. Gradient concentrations of Pegmolesatide and ESPO 3000 were incubated with 2 nM EPOR at 4 ℃ for 18 h; then, each concentration mixture was flowed through the EPO chip. The response value of EPOR binding to EPO was obtained. A nonlinear regression model was used to draw a sigmoid dose-inhibition curve and calculate the IC50 value

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us